Mycotech-Pharma
Mycotech Pharma is a Norwegian biotech spin-off of ImmunoPharma that develops and commercializes mushroom-based nutraceuticals built on an exclusive Agaricus blazei Murill strain and the proprietary AndoSan extract. The company serves cancer, chronic inflammation, and preventive anti-viral consumer segments via healthcare professional channels backed by 20+ peer-reviewed publications.
- Company typePrivate
- Founded2022
- HeadquartersOslo, Norway
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What Mycotech-Pharma does
Mycotech Pharma is a Norwegian biotechnology company founded in February 2022 as a spin-off of ImmunoPharma to develop and commercialize mushroom-based nutraceuticals. The company is headquartered in Oslo with 1-10 employees and is led by a management team that includes biotech entrepreneurs with prior operating experience at Biovotec, Dynal Biotech, and Axis-Shield. The core technology centers on an exclusive strain of Agaricus blazei Murill (ABM) mushroom, manufactured through a vertically integrated supply chain from cultivation to finished extract. The proprietary AndoSan extraction process produces a natural extract from three mushrooms that has been the subject of research at Norwegian institutions since 2000, resulting in more than 20 original publications and 4 completed Ph.D. degrees, with a U.S. patent granted in 2020 covering AndoSan's inhibition of the cancer-promoting enzyme legumain.
The company generates revenue through dietary supplement sales distributed via food and dietary supplement channels, with primary customer segments including cancer patients seeking supportive therapy alongside conventional treatment, individuals with chronic inflammatory conditions (ulcerative colitis, Crohn's disease, allergies), and consumers seeking preventive anti-viral support. The go-to-market model is sales-led and centered on healthcare professional engagement, including therapists, doctors, and clinical research institutions, supplemented by product launch events (e.g., the Andovir launch at Grand Hotel Oslo) and earned media such as a CEO appearance on the Norwegian TV program Helseposten with over 300,000 regular viewers. The flagship AndoSan product was joined by Andovir, an anti-viral mouth spray combining AndoSan with Cistus plant extracts, launched in January 2024 and targeting a broader consumer audience.
In January 2024, the company expanded its strategic footprint via a clinical study partnership with Berlin-based Analyze & Realize evaluating AndoSan in colorectal cancer patients with Cancer Related Fatigue, explicitly designed to enable subsequent market introduction in Germany by end of 2024. Mycotech Pharma also maintains a Japan operation under CEO Japan Hiroyuki Tanaka, and partners with Vivacell Biotechnology (Freiburg) for preclinical anti-viral research and with Oslo University Hospital, the Norwegian Institute of Public Health, and the Norwegian University of Life Sciences for clinical research support.
Mycotech-Pharma firmographics
Firmographics- Name
- Mycotech-Pharma
- Legal name
- Mycotech Pharma
- Website
- https://mycotechpharma.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Mycotech Pharma is a Norwegian biotech spin-off of ImmunoPharma that develops and commercializes mushroom-based nutraceuticals built on an exclusive Agaricus blazei Murill strain and the proprietary AndoSan extract. The company serves cancer, chronic inflammation, and preventive anti-viral consumer segments via healthcare professional channels backed by 20+ peer-reviewed publications.
- Ownership category
- akta.pro rank
Mycotech-Pharma industry classification
Industry- Product category
- Nutraceuticals and Dietary Supplements
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Herbal & Botanical Supplements (CRADAGAD)
- akta.pro secondary industry
- Probiotics & Digestive Health Supplements (CRADAGAF)
Keywords
Where Mycotech-Pharma is headquartered
LocationHeadquarters
- HQ city
- Oslo
- HQ country
- Norway
- HQ region
- Europe
Offices2 records
Markets served
Mycotech-Pharma business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations
Revenue model
- AndoSan Dietary Supplement Sales: Sale of AndoSan, a unique natural extract derived from three mushrooms, sold as a dietary supplement to support conventional cancer treatment and chronic inflammatory conditions. Distributed through food and dietary supplement channels.
- Andovir Anti-Viral Mouth Spray Sales: Sale of Andovir, an anti-viral mouth spray combining AndoSan with Cistus plant extracts for preventive use against viral infections.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Mycotech-Pharma product offering
Product offeringCore offering
Mycotech Pharma develops and commercializes mushroom-based dietary supplements derived from an exclusive strain of Agaricus blazei Murill (ABM). Its flagship product, AndoSan, is a proprietary extract from three mushrooms formulated to support immune function, reduce inflammation, and complement conventional cancer treatment. The company has expanded into preventive health with Andovir, an anti-viral mouth spray launched in 2024 that combines AndoSan with Cistus plant extracts to inhibit viral entry into human cells.
Product overview
Mycotech-Pharma is a biotechnology company developing and commercializing mushroom-based health products derived from an exclusive strain of Agaricus blazei Murill (ABM). The company operates two main products: AndoSan, the flagship mushroom extract supplement for immune health and inflammatory response optimization, and Andovir, an anti-viral mouth spray launched in February 2024 that combines AndoSan with Cistus plant extracts. Both products are positioned as supportive treatments for conventional medical care, including cancer treatment and chronic inflammatory conditions.
Differentiator
Problem solved
Functional benefit
Brands
- Andosan: A unique natural extract derived from three mushrooms through a proprietary process. Scientifically backed to optimize immune function and inflammatory responses. Ideal support for conventional cancer treatment and natural support for treatment of chronic inflammatory conditions such as IBD.
- Andovir
Products and services
- AndoSan
- Andovir
Quantifiable outcome
- Reduces tumor load in intestinal cancer (preclinical studies in A/J Min/+ mouse model)
- +6 more outcomes
Companies that use Mycotech-Pharma
Customer profileNamed customers6 records
Segments6 records
Ideal customer profiles5 records
Mycotech-Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Mycotech-Pharma partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Analyze & Realize - Cancer Related Fatigue StudycorePartnership to conduct clinical study evaluating potential benefits of AndoSan in subjects with colorectal cancer experiencing Cancer Related Fatigue. Study will measure fatigue scores, cytokines in blood, and changes in intestinal bacteria flora (Microbiome). Planned to finish by end of 2024. Strategic focus on German market introduction.
- Analyze & Realize (a-r.com)coreLeading European consultancy helping guide the registration and documentation of Andosan's clinical effects. Recently signed agreement to conduct a clinical study evaluating AndoSan benefits for colorectal cancer patients experiencing Cancer Related Fatigue (CRF). Recognized authority in consumer healthcare sector with unique focus on natural health products and over 300 clinical trials completed.
- Vivacell BiotechnologycoreBased in Freiburg, documents the effect of natural substances on human cells, including cancer cells. Conducted cell assay studies in 2022 revealing AndoSan reduced SARS-CoV-2 spike protein binding to ACE2 receptors by up to 40%. Provided preclinical research supporting Mycotech's patent applications.
- Oslo University Hospital (OUS)coreMajor Norwegian research institution where Professor Geir Hetland conducts research on AndoSan. Multiple clinical studies conducted at the hospital, including studies on multiple myeloma patients and allergy sufferers.
- Norwegian Institute of Public Health (NIPH)minorNorwegian government health institution involved in clinical research on AndoSan.
- Norwegian University of Life Sciences (NMBU)minorNorwegian university that has conducted research on AndoSan, including Master's theses on the extract's protein composition.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Mycotech-Pharma competitors and assessment
Company assessmentDirect peers
- Hifas da Terra: Spanish biotechnology company developing premium medicinal mushroom extracts (including Agaricus, Ganoderma, Cordyceps) with clinical research backing for immune and oncological supportive care. Direct peer to Mycotech in the evidence-backed medicinal mushroom supplement category.
- Oriveda: Premium medicinal mushroom extract company selling high-potency single-species extracts with a strong focus on active compound standardization. Comparable to Mycotech's positioning on quality, exclusivity, and evidence-based differentiation in the ABM/herbal extract category.
- Host Defense (Fungi Perfecti): Paul Stamets' medicinal mushroom supplement company offering mycelium-based immune support products. Comparable to Mycotech in the medicinal mushroom consumer category, though broader in species coverage and larger scale.
- Real Mushrooms: Medicinal mushroom supplement brand focused on 100% fruiting body extracts with high beta-glucan content. Comparable to Mycotech's premium, science-forward positioning in the medicinal mushroom extract category.
- Four Sigmatic: Consumer wellness brand built around functional mushroom products (coffee, elixirs, supplements). Comparable to Mycotech in consumer-facing medicinal mushroom products, though with a more mass-market positioning and broader SKU range.
- Nammex (North American Medicinal Mushroom Extracts): B2B supplier of certified organic medicinal mushroom extracts to supplement brands. Comparable to Mycotech in supplying standardized, evidence-backed mushroom extracts, with overlap on quality, traceability, and active-compound standardization.
Emerging players
- MycoTechnology: US-based company using fermentation technology to develop novel food and nutrition ingredients, including mycelium-based protein. Comparable to Mycotech in applying proprietary fungal technology to health/nutrition applications, but focused on B2B food ingredients rather than consumer supplements.
Broad incumbents
- Gaia Herbs: Large US-based herbal supplement company with broad botanical product portfolio including immune support, stress, and sleep. Comparable to Mycotech in the botanical/herbal supplement category but at much larger scale with broader indications.
- New Chapter: Established supplement brand (acquired by Procter & Gamble) with broad herbal and mushroom-based immune support products. Comparable to Mycotech in the medicinal mushroom/immune health category but as a mass-market incumbent.
Others
- ImmunoPharma: Norwegian parent company of Mycotech Pharma and owner of Eqology. Relevant as the originating entity, equity holder, and shared ecosystem partner for the AndoSan product platform.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Mycotech-Pharma social profiles
Digital presenceMycotech-Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mycotech-Pharma leadership team
Management profileNumber of profiles
Profiles5 records
Mycotech-Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mycotech-Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mycotech-Pharma
What does Mycotech-Pharma do?
Mycotech Pharma develops and commercializes mushroom-based dietary supplements derived from an exclusive strain of Agaricus blazei Murill (ABM). Its flagship product, AndoSan, is a proprietary extract from three mushrooms formulated to support immune function, reduce inflammation, and complement conventional cancer treatment. The company has expanded into preventive health with Andovir, an anti-viral mouth spray launched in 2024 that combines AndoSan with Cistus plant extracts to inhibit viral entry into human cells.
Is Mycotech-Pharma a public or private company?
Mycotech-Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mycotech-Pharma founded?
Mycotech-Pharma was founded in 2022. It employs 1 to 10 people.
Where is Mycotech-Pharma based?
Mycotech-Pharma is headquartered in Oslo, Norway, in the Europe region.
How does Mycotech-Pharma make money?
Two revenue lines are on record. AndoSan Dietary Supplement Sales are the primary driver. The others are andovir Anti-Viral Mouth Spray Sales.
Who are Mycotech-Pharma's main competitors?
Direct peers on record are Hifas da Terra, Oriveda, Host Defense (Fungi Perfecti), Real Mushrooms, Four Sigmatic and Nammex (North American Medicinal Mushroom Extracts). MycoTechnology is listed as an emerging player. Broad incumbents are Gaia Herbs and New Chapter. ImmunoPharma is listed as an others.
Does Mycotech-Pharma have an API?
No public API is recorded for Mycotech-Pharma.
What industry is Mycotech-Pharma in?
Mycotech-Pharma's product category is Nutraceuticals and Dietary Supplements. Its primary akta.pro industry code is CRADAGAD, Herbal & Botanical Supplements, with a secondary code of CRADAGAF, Probiotics & Digestive Health Supplements. Its NAICS code is 325411 and its SIC code is 2833.